Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sovleplenib - HUTCHMED

Next Previous
Search
Drug Profile

Sovleplenib - HUTCHMED

Alternative Names: HMPL-523; HMPL-523 acetate

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer Hutchison MediPharma; HUTCHMED
  • Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Morpholines; Piperidines; Pyrazines; Pyridones; Small molecules; Sulfones
  • Mechanism of Action Immunomodulators; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Idiopathic thrombocytopenic purpura
  • Phase II/III Autoimmune haemolytic anaemia
  • Phase I B-cell lymphoma; Haematological malignancies; Lymphoma; Unspecified
  • No development reported Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • Discontinued Lupus vulgaris; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 07 Dec 2024 Updated efficacy and adverse event data from a phase III ESLIM-01 trial in Idiopathic thrombocytopenic purpura was presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 05 Nov 2024 Efficacy and adverse events data from phase-III ESLIM-01 trial for Idiopathic thrombocytopenic purpura released by HUTCHMED
  • 31 Jul 2024 HUTCHMED anticipates the regulatory approval for sovleplenib in Idiopathic thrombocytopenia purpura in China, at the end of year 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top